Completed PHASE1 INTERVENTIONAL NCT00152100

Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome

Transplantation of Highly Purified Haploidentical CD133 Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome

Sponsor: St. Jude Children's Research Hospital

Conditions Severe Combined Immunodeficiency

Interventions Filgrastim, Alemtuzumab Miltenyi CliniMACS Stem cell transplant

Updated 5 times since 2017 Last updated: May 19, 2009 Started: Feb 29, 2004 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Severe Combined Immunodeficiency and is currently completed. St. Jude Children's Research Hospital leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

St. Jude Children's Research Hospital

Data source: St. Jude Children's Research Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Memphis, United States